Other News

Endovascular Engineering’s Hēlo™ Thrombectomy System Receives IDE Approval to Start ENGULF Pivotal Trial for the Treatment of Pulmonary Embolism

MENLO PARK, Calif., Jan. 11, 2024 /PRNewswire/ — Endovascular Engineering (“E2”), a medical device company focused on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism (VTE), announced today FDA Investigational Device Exemption…

Arineta Cardio Imaging Appoints Industry Veteran Doug Ryan as New CEO

Caesarea, Israel – January 9, 2024 – Arineta Cardio Imaging, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, welcomes its new CEO Doug Ryan to its international team. Ryan brings 30 years of experience creating business infrastructure and crafting market strategies for medical device companies to his role […]

Ultromics Announces Partnership to Expedite Development of Echo AI Algorithm for Early Detection of Cardiac Amyloidosis

OXFORD, England, Jan. 10, 2024 /PRNewswire/ — Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with Pfizer to support the validation and FDA clearance of its AI-based technology for the…

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated […]

Cleerly® Launches Cleerly® ISCHEMIA™ Solution for Heart Disease Analysis

DENVER–(BUSINESS WIRE)–Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the launch of Cleerly ISCHEMIA, which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance. Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool, intended […]

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication of new groundbreaking data reflecting the clinical impact of its flagship advanced preservation device, the Paragonix SherpaPak Cardiac Transport System (CTS), to protect and monitor donor hearts from extended criteria donors. In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for

Endologix Announces that Scott Ward Joins Board of Directors

IRVINE, Calif.–(BUSINESS WIRE)– Endologix Inc. LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Scott Ward has been appointed to the Endologix Board of Directors. Scott Ward was most recently the CEO and Chairman of the […]